

Article

Peptide-decorated nanofibrous niche augments in vitro directed osteogenic conversion of human pluripotent stem cells

Yi Deng, Yuanyi Yang, and Shicheng Wei

Biomacromolecules, **Just Accepted Manuscript** • DOI: 10.1021/acs.biomac.6b01748 • Publication Date (Web): 09 Jan 2017Downloaded from <http://pubs.acs.org> on January 11, 2017

Just Accepted

“Just Accepted” manuscripts have been peer-reviewed and accepted for publication. They are posted online prior to technical editing, formatting for publication and author proofing. The American Chemical Society provides “Just Accepted” as a free service to the research community to expedite the dissemination of scientific material as soon as possible after acceptance. “Just Accepted” manuscripts appear in full in PDF format accompanied by an HTML abstract. “Just Accepted” manuscripts have been fully peer reviewed, but should not be considered the official version of record. They are accessible to all readers and citable by the Digital Object Identifier (DOI®). “Just Accepted” is an optional service offered to authors. Therefore, the “Just Accepted” Web site may not include all articles that will be published in the journal. After a manuscript is technically edited and formatted, it will be removed from the “Just Accepted” Web site and published as an ASAP article. Note that technical editing may introduce minor changes to the manuscript text and/or graphics which could affect content, and all legal disclaimers and ethical guidelines that apply to the journal pertain. ACS cannot be held responsible for errors or consequences arising from the use of information contained in these “Just Accepted” manuscripts.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Peptide-decorated nanofibrous niche augments *in vitro* directed osteogenic conversion of human pluripotent stem cells

Yi Deng¹, Yuanyi Yang⁴, Shicheng Wei^{2,3,*}

¹ School of Chemical Engineering, Sichuan University, Chengdu 610065, China

² Department of Oral and Maxillofacial Surgery, School and Hospital of Stomatology, Peking University, Beijing 100081, China

³ Center for Biomedical Materials and Tissue Engineering, Academy for Advanced Interdisciplinary Studies, Peking University, Beijing 100081, China

⁴ Department of Materials Engineering, Sichuan College of Architectural Technology, Deyang 618000 China

1
2
3 **ABSTRACT:** Realization of clinical potential of human pluripotent stem cells (hPSCs) in bone
4
5 regenerative medicine requires development of simple and safe biomaterials for expansion of
6
7 hPSCs followed by directing their lineage commitment to osteoblasts. In the present study, a
8
9 chemically defined peptide-decorated polycaprolactone (PCL) nanofibrous microenvironment
10
11 was prepared through electrospinning technology and subsequent conjugation with vitronectin
12
13 peptide to promote the culture and osteogenic potential of hPSCs *in vitro*. The results indicated
14
15 that hPSCs successfully proliferated and maintained their pluripotency on the biointerface of
16
17 peptide-conjugated nanofibers without Matrigel under defined conditions. Moreover, the
18
19 prepared niche exhibited an appealing ability in promoting directed differentiation of hPSCs to
20
21 osteoblastic phenotype without embryoid body formation step, determined from the cell
22
23 morphological alteration, alkaline phosphate activity, and osteogenesis-related gene expression,
24
25 as well as protein production. Such well-defined, xeno-free and safe nanofiber scaffolds that
26
27 allow the survival and facilitate osteo-differentiation of hPSCs provide a novel platform for
28
29 hPSCs differentiation *via* cell-nanofiber interplay, and possess great value in accelerating the
30
31 translational perspectives of hPSCs in bone tissue engineering.
32
33
34
35
36
37

38 **KEYWORDS:** Peptide, polycaprolactone, nanofiber, human pluripotent stem cells, osteogenic.
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1. INTRODUCTION

In contrast to adult stem cells, human pluripotent stem cells (hPSCs), including human embryonic stem cells (hESCs) and human induced pluripotent stem cells (hiPSCs), possess the remarkable capacity to self-renew and give rise to all major lineages of somatic cells, therefore, they have become promising candidates for regenerative medicine and tissue engineering application.^{1, 2} Compared with hESCs, hiPSCs originated from human autologous cells circumvent the concerns regarding ethical issues and immune properties, making them ideal seed cells for regenerative medicine.^{3, 4} Generally, hPSCs are cultured and differentiated on Matrigel that extracted from Engerbreth-Holm-Swarm (EHS) mouse sarcomas containing not only basement membrane components, but also plentiful inhibitors, growth factors, and a broad variety of unknown proteins, which brought about problems associated with microbial/viral contamination, immunogenicity, and variability of experimental results.⁵⁻⁷ Progress in engineering chemically defined microenvironment for proliferation and osteogenic commitment of hPSCs is stringently needed for their clinical bone regenerative applications. Up to now, many natural and recombinant extracellular matrix (ECM) proteins and their fragments, such as vitronectin,⁸ laminin,⁹ and collagen,¹⁰ have been exploited to maintain the self-renewal of hPSCs. Nevertheless, the significant quality variance from lot-to-lot and high cost for large scale cultivating of hPSCs resides in these biological matrices. Additionally, in terms of bone regenerative therapies, despite of the advantages that hPSCs offer, controlling their differentiation into targeted bone cells still remains a tough challenge. Hence, much effort should be made in developing economical and easily fabricated safe surfaces for multiplication of hPSCs followed by hastening their osteogenic differentiation and maturation.^{11, 12}

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Currently, several three-dimensional (3D) nanofibrous scaffolds made from synthetic and natural polymers have been constructed for modulating growth and improving osteogenic outcome of hPSCs consideration for the following reasons: (1) the topological structure and biomechanical performance of 3D nanofibers are akin to native ECM;^{13, 14} (2) 3D nanofiber microenvironment enables to expedite the osteogenic conservation of stem cells.¹⁵⁻¹⁷ For instance, a poly(l-lactic acid)/poly-benzyl-l-glutamate/collagen (PLLA/PBLG/Col) ternary nanofibrous scaffolds were fabricated by eletrospining and were proved by Ramakrishnaa et al. to promote greater osteogenic differentiation of adipose derived stem cells (ADSC) in the absence of an induction medium as evident from the enzyme activity and mineralization profiles for bone tissue engineering.¹⁷ Ardeshiryajimi et al. found that nanofiber-based polyethersulfone (PES) scaffold could efficiently enhance the differentiation of embryoid bodies (EBs) generated from hiPSCs into osteoblastic lineage than tissue culture plastic in osteogenic inducing medium.¹⁶ (3) After osteogenic differentiation, 3D fibrous surfaces are reported to promote the osteoblastic maturation and retain the cellular functions of osteoblasts.¹⁸ Most of these studies, however, always use Matrigel to pretreat nanofiber surfaces for helping hPSCs attachment and proliferation. Furthermore, osteogenic differentiation of hPSCs on biomaterials usually involves the EB formation step¹⁹⁻²² making it difficult to elucidate the direct interrelation between biomaterials and hPSC differentiation. To the best of our knowledge, no study has been reported on the effect of nanofibrous scaffolds on the osteogenic differentiation of hPSCs without the induction of differentiation by EB formation. Polycaprolactone (PCL), a USA Food and Drug Administration (FDA) approved material, is widely employed in bone tissue engineering due to its bioresorbability, excellent biocompatibility as well as sound mechanical properties.²³ A synthetic RGD oligopeptide derived from vitronectin (VN) protein, one component of ECM, is

1
2
3 proved to support the adhesion and successful self-renewal of hESCs and hPSCs for > successive
4
5 20 passages.^{6, 24} In order to graft VN peptide onto PCL nanofibrous meshes through standard
6
7 NHS/EDC chemistry, carboxymethyl chitosan, a natural linear amino-polysaccharide, containing
8
9 a large number of amine and carboxyl groups was coated onto the electrospun nanofiber surface.
10
11 With nonimmunogenicity, biodegradability, good biocompatibility, and intrinsic antibacterial
12
13 properties, carboxymethyl chitosan (CMC) finds a wide range of applications in biomedical
14
15 field.^{25, 26} Simultaneously, it is also reported that CMC, the structural similarity to
16
17 glycosaminoglycans, enables to induce osteogenic differentiation of cells.^{27, 28} Herein, based on
18
19 these considerations, the resultant peptide-decorated nanofibrous niche was prepared and
20
21 evaluated for its role in supporting proliferation and stimulating osteo-differentiation of hPSCs
22
23 under defined biointerface for the first time. We believe that the work will help greatly accelerate
24
25 the introduction of hPSCs into bone repairing clinical applications cultivated in the chemically
26
27 defined and safe substrate.
28
29
30
31
32

33 34 35 36 **2. MATERIALS AND METHODS**

37 38 **2.1. Materials**

39
40 Polycaprolactone (PCL, $M_w \approx 80000$ g/mol) was provided by Sigma-Aldrich (St. Louis,
41
42 USA), and phosphate buffered saline (PBS) was obtained from ZSGB-Bio Ltd. (Beijing,
43
44 China). N-(3-(Dimethylamino)propyl)-N'-ethylcarbodiimide hydrochloride (EDC), N-
45
46 hydroxysuccinimide (NHS), 2-(N-morpho)ethanesulfonic acid (MES), 1,1,1,3,3,3-Hexafluoro-
47
48 2-propanol (HFIP), and carboxymethyl chitosan (CMC, $M_w \approx 9.5-20.9$ kDa, degree of
49
50 carboxymethyl substitution ≥ 86 %) were purchased from Aladdin (Shanghai, China). To
51
52 facilitate chemical conjugation onto the material surface, the peptide was modified at its N-
53
54
55
56
57
58
59
60

1
2
3 terminal with a lysine-containing spacer. Vitronectin (VN) peptide [Ac-KGGPQVTRGDVFTMP
4 sequence], supplied from Chinapeptides Co., Ltd. (Shanghai, China), were synthesized by a
5 batchwise fmoc-poly-amide method and had more than 98 % purity per the high-pressure liquid
6 chromatography profile. The primary antibodies including rabbit monoclonal antihuman Oct-4,
7 rabbit monoclonal antihuman SSEA-3, mouse monoclonal antihuman Tra-1-60, mouse
8 monoclonal antihuman Nanog, mouse monoclonal antihuman SSEA-4, rabbit monoclonal
9 antihuman Runx2, rabbit monoclonal antihuman Colla1, mouse monoclonal antihuman OPN,
10 and mouse monoclonal antihuman OCN, were all purchased from Cell Signaling Technology
11 (USA). All other chemicals were of analytical reagent grade, and all aqueous solutions were
12 prepared with deionized water (D.I. water).
13
14
15
16
17
18
19
20
21
22
23
24
25

26 27 **2.2. Preparation of electrospun PCL nanofibers**

28
29 PCL was first dissolved in HFIP at a concentration of 10 % (w/v, PCL/HFIP) by ultrasonic
30 and vigorous stirring overnight to obtain a homogenous solution. Afterwards, the solution was
31 placed into a syringe with a stainless-steel blunt needle (23 G) whose inner diameter is 0.5 mm.
32 Electrospinning of PCL nanofibers was carried out using a commercial electrospinning
33 equipment (SS-2535, YongKang Technology Co., Ltd., China) with a rotating collector covered
34 with Al foil. The electrospinning parameters were set at the applied voltage of 15 kV, the
35 collection distance of 10 cm, and the feed rate of 1.0 mL/h. The as-prepared electrospun fibrous
36 meshes were vacuum-dried at room temperature to remove residual organic solvent for future
37 use.
38
39
40
41
42
43
44
45
46
47
48
49

50 51 **2.3. Immobilization of CMC and peptide on the surface of nanofibers**

52
53 After being thoroughly washed, the samples were immersed in 3 w/v% CMC solution for 24 h
54 at 37 °C in a constant-temperature shaker (ZWY-103B, Shanghai ZHICHENG
55
56
57
58
59
60

1
2
3 Analytical Instrument Manufacturing Co., Ltd.), and then the treated samples were thoroughly
4 rinsed to remove the physically-absorbed CMC, which were named as CMC-PCL. To
5 conjugate VN peptide on the surface, the PCL-CMC samples were firstly pretreated by 2 mM
6 EDC and 5 mM NHS in 0.1 M MES buffer (pH= 5.6) for 40 min. Then, VN peptide solution
7 (1 mM, dissolved in sterile PBS buffer) was incubated onto the carboxyl-rich CMC-grafted
8 PCL nanofiber in 4 °C refrigerator for another 24 h. The resulting peptide-decorated
9 nanofibrous scaffolds (denoted as pep-CMC-PCL) were thoroughly washed by D.I. water and
10 dried under nitrogen influx before characterization and cell experiment. VN-decorated glass
11 slides (named as pep-CMC-glass) were also prepared in the light of the same process as
12 control group.
13
14
15
16
17
18
19
20
21
22
23
24
25

26 27 **2.4. Surface characterization**

28
29 Fourier transform infrared with attenuated total reflection (ATR-FT-IR) spectra (Magna-IR
30 750, Nicolet, USA) were collected to analyze the functional groups of the products in the
31 range of 400 cm⁻¹ to 4000 cm⁻¹.
32
33
34
35

36 The surface hydrophilicity was determined by a contact angle goniometry (SL200B, Kino,
37 Norcross, USA) equipped with a high-resolution camera based on the sessile drop method
38 using 2 mL of D.I. water droplets under ambient temperature and humidity. Surface energy
39 was further calculated by the matching software from Kino Industry
40 (<http://www.uskino.com/article/65.html>). Measurements were taken until droplets were well
41 settled on samples and repeated in triplicate, at six different positions per substrate type.
42
43
44
45
46
47
48
49

50 Surface topologies of the various treated substrates were characterized by a field emission
51 scanning electron microscope (FE-SEM, JSM-6701F, JEOL, Japan) at an accelerating voltage
52 of 20 kV. All samples were coated by gold for 30 s before SEM observation.
53
54
55
56
57
58
59
60

1
2
3 Atomic force microscopy (AFM, Dimension ICON, Bruker) was employed in contact modes
4
5 (a Si_3N_4 cantilever with a spring constant of 0.12 N/m) in dry condition to assess morphological
6
7 characteristics of the bare and modified PCL substrates. Surface roughness including
8
9 arithmetic average roughness (Ra) and root mean square roughness (Rq) were also calculated
10
11 from the roughness profile, and each sample was tested in sextuplicate to improve the statistics.
12
13

14
15 The alteration of chemical constituents and elemental states of the different PCL samples were
16
17 analyzed by X-ray photoelectron spectroscopy (XPS, Kratos Analytical Ltd., Manchester, UK)
18
19 for both survey and high-resolution spectra. The binding energies were calibrated by the C 1s
20
21 hydrocarbon peak at ~285 eV. Besides, the quantitative analysis and curve fitting were
22
23 conducted using the CasaXPS software package.
24
25

26
27 To know whether the peptide was grafted onto the nanofiber surface or not, the FITC-labeled
28
29 VN peptide (FITC-VN) was applied to anchor onto the active CMC-PCL substrate through
30
31 NHS/EDC chemistry in 4 °C for 24 h. Afterward, samples were rinsed with PBS and captured
32
33 under laser scanning confocal microscope (LSCM, Carl Zeiss, Germany) to visualize the
34
35 attached peptide at 488 nm excitation wavelength and 525 nm emission wavelength.
36
37

38 **2.5. Cell culture and seeding**

39
40 The hiPSCs (hNF-C1 line, provided by Chinese Academy of Sciences, GIBH, Guangzhou,
41
42 China) were generated from dermal fibroblasts by retroviral introduction of four Yamanaka's
43
44 factors: Oct3/4, Sox2, Klf4 and c-Myc. The hESCs (H9 line, supplied from GIBH) from the
45
46 inner cell mass (ICM) of blastocyst-stage embryos were also used in the present study. Matrigel
47
48 (BD Biosciences, Canada) was diluted with Dulbecco's modified eagle medium/F12
49
50 (DMEM/F12, Gibco, USA) at a ratio of 1:160 at 4 °C. Two sorts of hPSCs were cultured on
51
52 Matrigel-coated plates using chemically defined mTeSRTM1 medium (StemCell Technologies,
53
54
55
56
57
58
59
60

1
2
3 Canada) containing 10 μM Rock inhibitor (Y-27632, Selleck Chemicals, USA), and 1 v/v%
4
5 penicillin/streptomycin (Invitrogen, USA) at 37 °C in a humidified 5 % (v/v) CO₂ incubator
6
7 (MCO-18AIC, Japan). Cells between 30-50 times of passages were used for the *in vitro*
8
9 experiments. Cells were fed daily and passaged at 1:3 splitting ratio every 3-4 days by
10
11 exposure to EDTA (Aladdin, Shanghai, China) at 0.125 wt/v% for 5.5 min. Prior to cell
12
13 experiments, the prepared meshes were cut into round shape and sterilized with 75 % ethanol
14
15 for 1 h, followed by thorough rinse with disinfected PBS buffer. When reaching 70-75 %
16
17 confluence, cells were dissociated with EDTA, counted and seeded onto fibrous scaffolds at a
18
19 density of 1.6×10^5 cells per mL.
20
21
22
23

24 **2.6. Cell growth and pluripotency**

25 **2.6.1. Cell proliferation assay**

26
27
28 Cell viability of hiPSCs and hESCs on samples was evaluated using cell counting assay kit-
29
30 8 (CCK-8, Dojindo Laboratories, Kumamoto, Japan) following the manufacturer's protocol.
31
32 At desired time intervals (12 h, and 1 day-5 days) of cultivation, CCK-8 solution was added
33
34 into each well at a proportion of 1:10 (v/v) for 2 h incubation in the dark. Then 100 μL of
35
36 supernatant from each well was transferred to new 96-well cell culture plates using a pipette.
37
38 The absorbance value of the supernatant optical density (OD value) for each group was
39
40 measured with a microplate reader (model 680, Bio-Rad, Canada) at 450 nm wavelength with
41
42 a reference wavelength of 630 nm. hPSCs cultured on pep-CMC-glass were served as control
43
44 group. Six parallel specimens were used to provide an average and standard deviation.
45
46
47
48
49

50 **2.6.2. SEM observation of cells**

51
52 The typical cellular morphology on the fibrous scaffold in mTeSRTM1 was evaluated by FE-
53
54 SEM (JSM-6701F). Basically, after 1 and 3, 5 days incubation, the samples with cells were
55
56
57
58
59
60

1
2
3 taken from culture plates, rinsed with PBS buffer and fixed in 2.5% glutaraldehyde solution for
4
5 30 min, followed by dehydration with graded ethanol solutions (50 %, 70 %, 80 %, 90 %, 95 %, 100 %, 10 min each concentration) and dried for SEM observation (JSM-6701F).
6
7
8
9

10 **2.6.3. Cell pluripotency test**

11
12 Both hiPSCs and hESCs were cultured on peptide-decorated nanofibers in 24-well plates for 1
13 day and 3 days, respectively. The hPSCs before osteoinductive differentiation surface were
14 subjected to immunofluorescence analysis. They were fixed with 4% (v/v) paraformaldehyde for
15 15 min and permeabilized with 0.1% (v/v) Triton X-100 (Solarbio, Beijing, China) for 10 min at
16 room temperature. Afterward, they were incubated with 1 % bovine serum albumin/PBS buffer
17 at 37 °C for 30 min to block nonspecific binding. Then, cells were incubated with diluent
18 primary antibodies Oct-4 (1:1000 dilution), SSEA-3 (1:400 dilution), and SSEA-4 (1:400
19 dilution), and Tra-1-60 (1:200 dilution) at 4 °C overnight. After incubation with primary
20 antibodies, cells were washed thrice with PBS and incubated for 1 h at room temperature with
21 FITC-488 goat antirabbit (1:100, XSG-BIO) and TRITC-543 goat antimouse (1:100, XSG-BIO) secondary antibodies. All staining steps were followed by three washes in PBS buffer.
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Fluorescence signals were viewed immediately under LSCM (Carl Zeiss).

41 **2.7. Osteogenic induction**

42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Osteoinductive medium comprised fresh low-glucose DMEM containing 10% fetal bovine serum (FBS, Gibco, Carlsbad, Canada), 100 U/mL penicillin, and 100 mg/mL streptomycin (Invitrogen), 50 µg/mL ascorbic acid, 10 mM sodium β-glycerophosphate, and 100 nM dexamethasone. The hPSCs were first attached to the nanofibrous substrates in mTeSR™1 medium for 2 day. Afterward, the culture medium was replaced by osteoinductive medium. The culture medium was refreshed every 2-3 days, and the whole process lasted for 28 days. Day 1

1
2
3 was referred to the day when osteogenic induction commenced, and Day 0 denoted the time
4
5 when cell before osteogenic stimulus.
6
7

8 **2.8. Osteogenic differentiation**

9 **2.8.1. Cell morphology observation**

10
11 Cellular morphology and spreading of hPSCs after osteogenic induction on samples were
12
13 also evaluated using SEM. After different induction time (Day 0, 2, 7, 14, and 28), the
14
15 scaffolds with cells were fixed in 2.5% glutaraldehyde solution, dehydrated with graded
16
17 ethanol solutions, and dried for SEM observation (JSM-6701F).
18
19
20
21

22 **2.8.2. Alkaline phosphatase (ALP) activity**

23
24 ALP activity of hiPSCs and hESCs on samples was carried out by an ALP assay reagent kit
25
26 (Nanjing Jiancheng Bioengineering Institute, China) following the manufacturer's instruction.
27
28 A 1 mL cell suspension was seeded on peptide-decorated nanofibrous niche and peptide-
29
30 decorated glass slides at a density of 1.6×10^5 cells/mL in 24 well-plate. After Day 0, 4, 7, 14,
31
32 and 21 of osteoinduction, the supernatant was removed and 100 μ L of lysis solution (1%
33
34 TritonX-100) was added into each well and incubated for 1 h. After that, 30 μ L of resulting
35
36 cell lysates at each well was transferred to new 96-well cell culture dishes, and cultivated with
37
38 50 μ L of carbonated buffer solution (pH= 10) and 50 μ L of substrate solution (4-amino-
39
40 antipyrine) at 37 °C for 15 min. Then 150 μ L of potassium ferricyanide (chromogenic agent)
41
42 was added into the mixed solution and the production of *p*-nitrophenol was determined by the
43
44 absorbance at 520 nm on a microplate reader (Elx-800, Bio-Tek Instruments, USA). For
45
46 normalization, the total protein concentration was measured using a bicinchoninic acid (BCA)
47
48 protein assay kit (Thermo, USA). Thus, ALP activity was normalized and expressed as the
49
50 total protein content (U/g of prot). Six specimens were tested for each incubation period.
51
52
53
54
55
56
57
58
59
60

1
2
3 Meanwhile, enzyme-histochemistry (EHC) staining was also performed to visualize ALP
4 distribution and expression on sample surface at the same time points using a BCIP/NBT ALP
5 color development kit (Beijing ComWin Biotech, China).
6
7
8
9

10 **2.8.3. RNA extraction and quantitative real-time PCR**

11
12 After Day 7, 14, and 21 of osteoinduction, the total mRNA was isolated from cells using
13 TRIZol (Invitrogen, USA) and reverse transcribed into cDNA using a Revert Aid First Strand
14 cDNA Synthesis Kit (Thermo, USA) as per the manufacturer's instruction. Then, quantitative
15 real-time polymerase chain reaction (RT-PCR) analysis was conducted with SYBR SYBR Green
16 (Roche, USA) on an ABI 7500 RT-PCR machine (Applied Biosystems, USA). All were
17 performed in triplicate and the expression of glyceraldehyde-3-phosphate dehydrogenase
18 (GAPDH) was employed as house keeping gene. Primers (provided from Sangon Biotech,
19 Shanghai, China) used in the present study were listed in Table S1. Primer sets (10 mM final
20 concentration for each primer) were used in a volume of 20 mL per tube. The thermal profile of
21 the PCR was 50 °C for 2 min and 95 °C for 10 min, followed by 40 cycles at 95 °C for 5 s and
22 60 °C for 1 min. The cycle threshold values (Ct values) were applied to determine the fold
23 differences by $\Delta\Delta C_t$ method.
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40

41 **2.8.4. Immunofluorescence**

42
43 After different days (Day 7, 14, 21) of osteogenic stimulus, cells on samples were fixed with 4
44 % paraformaldehyde, permeabilized with 0.1 % Triton X-100. After rinsing with PBS, cells were
45 incubated with 1 % BSA/PBS buffer to block nonspecific binding. Then, cells were incubated
46 with osteogenesis-related primary antibodies Runx2 (1:400 dilution), Col1a1 (1:400), Nanog
47 (1:400 dilution), OPN (1:400 dilution), and OCN (1:400 dilution) at 4 °C overnight. The next
48 day, cells were incubated with secondary antibody (1:100, XSGB-BIO) at a dilution of 1:100 for
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 1 h in the dark at ambient temperature. Furthermore, the cytoskeleton was stained with 5
4
5 $\mu\text{g}/\text{mL}$ FITC-phalloidin (Sigma-Aldrich) for 30 min. The fluorescence signals in the cells were
6
7
8 observed by a LSCM (Carl Zeiss).
9

10 **2.9. Statistical analysis**

11
12 All the quantitative data were expressed as mean \pm standard deviation. Statistical analysis
13
14 was done using SPSS 10.0 software. One-way analysis of variance (ANOVA) or Student's t-
15
16 test was used to determine the significant differences among the groups, and p -values less than
17
18 0.05 were considered statistically significant.
19
20
21
22
23
24

25 **3. RESULTS AND DISCUSSION**

26 **3.1. Surface composition and morphology of peptide-decorated nanofibers**

27
28 In this study, a facile biomimetic method was applied to develop a 3D peptide-decorated
29
30 niche with the functions in supporting growth and boosting the osteogenic conversion of
31
32 hPSCs *in vitro* as schemed in Fig. 1. Briefly, the PCL nanofibers were prepared through
33
34 traditional electrospinning technology. To better immobilize peptide, CMC molecule as a
35
36 bridge (intermediate layer) was further grafted to the nanofibrous surface. The -COOH groups
37
38 on the resultant CMC-PCL surfaces were preactivated with the NHS/EDC chemistry to
39
40 facilitate the VN peptide tethering of terminal carboxyl groups to the NHS groups, producing
41
42 peptide tethering surfaces for culture of hPSCs without Matrigel and EB formation step.
43
44
45
46
47
48

49 To explore the alteration of chemical composition and morphology after different stages of
50
51 surface functionalization, the modified PCL nanofibrous meshes were characterized by FT-IR,
52
53 contact angle goniometry, XPS analysis and AFM, as well as SEM. The ATR-FT-IR spectra
54
55 of the functionalized samples were shown in Fig. 2a. The bands detected at 2866 cm^{-1} and
56
57
58
59
60

1
2
3 2944 cm^{-1} were corresponded to the characteristic absorption of C-H stretching vibrations. The
4
5 absorption band at approximately 1165 cm^{-1} and 1241 cm^{-1} was putatively assigned to the
6
7 symmetric and asymmetric stretching vibration of C-O-C in PCL.²⁹ The strong peak at 1723 cm^{-1}
8
9 were associated with C=O stretching bonds. These are the characteristic peaks of pure PCL.
10
11 After CMC modification, nonetheless, the new peaks at 1648 cm^{-1} and 1555 cm^{-1} obviously
12
13 showed up, which should be associated with the C=O stretching vibration of amide I ($\nu\text{C=O}$) and
14
15 the deforming vibration of amide II ($\delta\text{N-H}$) of CMC.³⁰ The typical broad peaks of hydroxy group
16
17 (OH) were observed at about 3378 cm^{-1} . In addition, the intensity of the three peaks was
18
19 enhanced which might result from the superimposed vibration of amido bond and hydroxy group
20
21 after introducing peptide onto CMC-PCL surface, suggesting that VN peptide was effectively
22
23 covalently bonded on CMC-grafted PCL nanofibers. The water contact angle on a substrate has
24
25 been extensively used to track and evaluate the effectiveness of surface modification protocols.
26
27 High contact angle values describe hydrophobicity, and low angles indicate hydrophilicity.
28
29 Initially, the bare PCL nanofiber was super-hydrophobic ($122.3 \pm 3.91^\circ$), corresponding to the
30
31 lowest surface free energy ($17.52 \pm 0.97 \text{ mJ/m}^2$) among them. The water contact angle on the
32
33 nanofiber after CMC anchoring dramatically decreased by about 82° , due to the hydrophilic
34
35 groups (-OH, -NH-C=O, and -NH₂) of the grafted CMC on the hydrophobic PCL surfaces.
36
37 Additionally, immobilization of the peptide onto the CMC-coated PCL nanofiber continuously
38
39 reduced the water contact angle to $23.8 \pm 1.0^\circ$ (surface free energy= $66.1 \pm 2.1 \text{ mJ/m}^2$) in Fig.
40
41 2b, attributing to the hydrophilic nature of peptide, which implied that VN peptide was
42
43 successfully grafted onto the PCL nanofiber *via* CMC interlayer. It is recognized that, in
44
45 biological systems, hydrophilic biointerface of implant is capable of promoting the adhesion and
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 proliferation of cells *via* increasing the adsorption of essential proteins in the cell culture
4
5 media.^{31, 32}
6

7
8 These findings were further verified by an XPS survey scan (Fig. 3, and Table S2). In the
9
10 full scan spectrum of pristine PCL nanofibers, carbon and oxygen elements were the
11
12 predominant components. Successful anchoring of CMC was indicated by an increase in the N
13
14 1s and O 1s content, and a corresponding decrease in the C 1s content from 78.29 % to 69.03
15
16 % as shown in Table S2. Upon attachment of peptide on the surface, notably in the wide-scan
17
18 spectra, the appearance of a sodium signal (because the peptide was dissolved in PBS buffer),
19
20 and the enhancement of nitrogen peaks (N 1s, from 2.26 % to 3.03 %) on the surface of pep-
21
22 CMC-PCL samples indicated successful tethering of VN peptide. Furthermore, an evident
23
24 change in the carbon bond composition observed in the high-resolution narrow carbon spectra
25
26 (C 1s) clearly supported these conclusions (Fig. 3b-d). The high-resolution C 1s spectrum of
27
28 the pristine PCL was deconvoluted into three different curves. The binding energies centered
29
30 at 284.6 eV, 286.1 eV and 288.7 eV could be assigned to the -C-C-/C-H-, -C-OH, and -C=O
31
32 bonds, respectively. After CMC coating, the intensity of the carbon skeleton (-C-C-/C-H-)
33
34 decreased dramatically from 52.91 % to 41.05 %, and the peaks of the hydroxyl (-C-OH) and
35
36 carbonyl (C=O) groups increased as shown in Fig. 3c. This should be attributed to the ample
37
38 hydrophilic groups of CMC. Whereas a broad peak of the -C-N- bond at about 285.3 eV was
39
40 newly recorded on both CMC-PCL and pep-CMC-PCL samples, indicating the presence of
41
42 CMC and peptide. Compared with that of CMC-PCL, the peaks of -C-N- and C=O for
43
44 peptide-conjugated samples were enhanced greatly in intensity due to the abundant presence
45
46 of amine groups and amide bonds (-NH-C=O) in the structure of VN peptide molecule, which
47
48 further proved the successful peptide tethering. Furthermore, by fitting the distribution of the
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 high-resolution N 1s spectra of CMC-coated and peptide-tethered PCL using Gaussian/Lorenz
4 curve, three peaks were obtained for both of them (Fig. S1). The peaks centered at 399.4 eV,
5 400.3 eV, and 401.5 eV were consistent with the protonated amine specie ($R-NH_3^+$), amide ($-$
6 $NH-C=O$), and amine bond ($R-NH_2$), respectively. We could see that the content of $-NH-C=O$
7 component in the total of N 1s line increased accompanied with the reduction of $R-NH_2$ and $R-$
8 NH_3^+ in the spectrum of pep-CMC-PCL sample, which might ascribe to the covalent bonding
9 formation between the negative COO^- group of CS and the $R-NH_2$ group of peptide.
10 More visually, under LSCM (Fig. S2), green fluorescent nanofibrous network structures were
11 observed when it modification with FITC-labeled peptide, further corroborating the loading of
12 VN peptide on the surface of PCL nanofibers. These results obviously indicated that peptide was
13 easily immobilized on the CMC-functionalized PCL surface.
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28

29 PCL nanofiber with immobilized CMC and peptide were analyzed by SEM and AFM to
30 investigate surface topology and roughness. As presented in Fig. 4, the pure PCL electrospun
31 meshes possessed a uniform and smooth surface morphology with the diameter of 2.56 ± 0.07
32 μm . The introduction of CMC, nevertheless, made the fibrous surface rough, and some nodule-
33 like structures were detected in CMC-PCL and pep-CMC-PCL fibers. Furthermore, the surface
34 roughness including R_a and R_q were also determined by AFM. Following CMC modification,
35 the relative roughness of CMC-PCL significantly increased from 789 ± 51 nm to 960 ± 62 nm
36 for R_a and from 931 ± 43 nm to 1162 ± 79 nm for R_q , compared with the pristine PCL
37 nanofibers. Addition of peptide also improved the surface roughness of the modified PCL
38 substrates. Based on the literature evidence, an appropriate rough microtopography can promote
39 osteoblastic conversion of hMSCs and accelerate ingrowth of soft and hard tissue into the
40 materials.³³⁻³⁵
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

3.2. Cell viability

The adhesion and proliferation of the hPSCs cultured on the VN peptide-riched fibrous scaffolds and glass slides for 12 h, and 1 day-5 days were determined by CCK-8 assay. Fig. 5 showed that a conspicuous increase in the cell proliferation was detected in all materials with increasing culture time, which could be considered the good cytocompatibility of biomaterials. In accordance with earlier work, VN peptide surface could promote hPSCs attachment and proliferation *via* RGD-cell integrin interaction, and hiPSCs adhesion is significantly influenced by the peptide density on the surface.^{6, 36} Compared with pep-CMC-glass group, the pep-CMC-PCL nanofibers displayed a lower vitality especially at long culture periods (3-5 days), implied that cells preferred to attach and grow on smooth two-dimensional (2D) surfaces than rough three-dimensional (3D) ones, which was in line with previous publications.^{37, 38} Gao et al. cultured hMSCs on both PCL nanofibrous scaffolds and glass surfaces, and observed that more stem cells were grown on glass compared with fibrous scaffolds regardless of in serum-contained and serum-free culture media.³⁷ Turng also found that mouse NIH3T3 cell attachment on poly(propylene carbonate) and poly(propylene carbonate)/chitosan nanofibers was lower than that of 2D tissue culture plastics.³⁸ Besides, comparing the two hPSCs, more hiPSCs were attached on the peptide-tethered nanofibrous scaffolds than hESC. Although 2D plate culture has an advantage over 3D fibrous scaffold culture regarding cell numbers, numerous literature has proved that nanofibrous surface plays an obvious promotive role on cell differentiation. Therefore, a variety of 3D nanofibers fabricated from synthetic and natural polymers were developed to manipulate and hasten the committed differentiation hPSCs to neuron/neurocyte-like,^{19, 39} hepatocyte-like,^{40, 41}

1
2
3 cardiomyocyte^{42, 43}, or primordial germ cells⁴⁴ and so on, but limited effort is put in
4
5 investigation the role of nanofibrous surfaces in osteogenic stimulation of hPSCs.
6
7

8 **3.3. Cell morphology and pluripotency**

9

10 In general, it is quite a challenge to support attachment and growth of hPSCs without Matrigel.
11
12 In order to examine the influence of the VN peptide-loaded nanofibers on the cellular
13 morphology and pluripotency, SEM observation and immunofluorescence staining of two hPSCs
14
15 were conducted. Undifferentiated hPSCs exhibited a high nucleus-to-cytoplasm ratio, formed
16
17 tightly packed colonies with defined colony borders, and expressed pluripotency markers.^{45, 46}
18
19 The hiPSCs and hESCs were both robustly attached onto the pep-CMC-PCL nanofibrous scaffold
20
21 with remarkable spreading after seeded for 24 h (Fig. 6), and maintained typical undifferentiated
22
23 morphology during 5 days of culture. The SEM image showed that hPSCs incubated on peptide-
24
25 decorated nanofibers grew in tightly packed colonies and defined colony borders. It was worth to
26
27 note that the size of hPSCs colonies increased with the extension of time, indicating that the
28
29 hPSCs could well proliferate on the peptide-decorated PCL nanofibers. By comparison, no cell
30
31 adhered on “bare” PCL nanofiber surface. Maintenance of pluripotency is a critical parameter
32
33 when evaluating new niches for hPSCs culture. Immunofluorescence staining was carried out to
34
35 estimate whether cells retained markers of undifferentiated hPSCs. The POU family transcription
36
37 factor Oct-4 is a highly specific and indispensable biomarker for undifferentiated hPSCs;⁴⁷
38
39 SSEA-4 and SSEA-3 are glycolipid cell surface antigens powerfully expressed in
40
41 undifferentiated hPSCs;⁴⁵ and Tra-1-60 expressed on podocalyxin is a stem cell-defining marker
42
43 found on the membrane surface of hPSCs.⁴⁸ Results revealed the strong positive staining of Oct-
44
45 4, Tra-1-60, SSEA-3, and SSEA-4 in cultures of the peptide-decorated surface throughout 1 and
46
47 3 days, indicating that hiPSCs and hESCs all remained their undifferentiated characteristics very
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 well on the peptide-decorated substrate during 3 days of culture. At the same time, cells on the
4
5 nanofibrous scaffolds exhibited the morphology most similar to undifferentiated hPSCs, as
6
7 characterized by compact colonies with several cells and large nuclei-to-cytoplasm ratios as
8
9 shown in Fig. 7. Spontaneous differentiation on the edges or in the center of the colonies was
10
11 rarely observed on the peptide-decorated substrate. Overall, these results demonstrate that a
12
13 short peptide sequence from VN protein conjugated on the PCL nanofibers could robustly
14
15 support hPSCs proliferation and maintain their pluripotency under a fully defined medium
16
17 (TeSRTM1). Compared with Matrigel-coated nanofibers, the peptide-decorated nanofibers
18
19 avoid the problems related to immunogenicity, microbial and viral contamination. Hence, our
20
21 VN peptide-decorated PCL nanofibers through CMC modification may be suitable for hPSCs
22
23 culture without Matrigel coating.
24
25
26
27
28

29 **3.4. Osteogenic differentiation**

30
31 For optimal expansion and differentiation of hPSCs in bone regenerative applications, it is
32
33 much-needed to design an osteogenic environment that mimics cell niche and induces
34
35 ossification of cells on chemically defined biomaterials. To evaluate whether the
36
37 hiPSCs/hESC enable being directly induced toward osteogenic lineages *in vitro*, the cellular
38
39 morphological alteration, the ALP activity, and the expression of osteogenesis-related genes,
40
41 as well as corresponding protein expression were assessed at specific time intervals.
42
43
44
45

46 **3.4.1. Cell morphology alteration**

47
48 Figure 8a-b presented a typical overview of hiPSCs and hESCs morphologies on sample
49
50 surfaces at Day 0, 2, 7, 14, 21 and 28 under SEM, respectively. Before osteogenic stimulus,
51
52 hPSCs colonies with intrinsic undifferentiated morphology were detected on the fibrous
53
54 scaffolds, whilst after directed differentiation in osteogenic media, apparent change in cell
55
56
57
58
59
60

1
2
3 morphology were found. The cell colonies collapsed to several parts, and some differentiated
4
5 cells with variable morphologies migrated from the periphery of hPSCs colonies on the peptide-
6
7 decorated nanofibers, indicating that hPSCs differentiation occurred at the edges of the colonies.
8
9
10 When time prolonged to Day 7 and Day 14, these differentiated cells possessed a low degree of
11
12 cell-cell contact area existed in the form of single cell, and they displayed a highly flattened
13
14 morphology with numerous filopodia, similar to osteoblastic morphology, which indicated that
15
16 net-like microstructure of nanofibers provided favorable environment for cell differentiation
17
18 owing to structural similarity to ECM. Moreover, at the high magnification, the presence of
19
20 abundant cellular filopodia demonstrated a good adhesion and spreading of cells. During 21 days
21
22 of osteoinduction, such phenomenon aggravated, however, the number of cells adhering to
23
24 modified PCL nanofibers decreased at Day 28, implying the excessive induction time in
25
26 osteogenic inducing media might adverse to cell growth/proliferation. The results indicated the
27
28 synergistic effect of osteoblast-inducing chemical factors (including β -glycerophosphate,
29
30 ascorbic acid and dexamethasone) and nanofibrous topological cue could accelerate the
31
32 osteogenic commitment of hPSCs. Meanwhile, the result also revealed that 21 days might be
33
34 the optimal time for osteogenic conservation of hPSCs under osteoinductive media.
35
36
37
38
39
40

41 **3.4.2. Alkaline phosphatase activity**

42
43 ALP, an early marker of osteogenesis, was expressed strongly in undifferentiated hPSCs, as
44
45 well as in the osteoblasts. As shown in Fig 9a, it was evident that there were distinguished ALP
46
47 expression between hiPSCs and hESCs on peptide-decorated PCL nanofibrous scaffolds. As for
48
49 hiPSCs, the production of ALP increased slightly during the first four days, and then decreased
50
51 to about zero after being induced for 7 days, indicating that hiPSCs began to lose their stem cell
52
53 properties. Later, the expression of ALP re-increased with the extent of time and kept at a high
54
55
56
57
58
59
60

1
2
3 level (72.1 ± 6.7 U/gprot) after 14 days, which signified the appearance of osteogenic
4 progenitors after 14 days of osteoinductive culture. Clearly, the ALP signal on VN peptide-
5 conjugated nanofiber group reached a substantially higher level compared with that of glass
6 group after Day 7, and the level of ALP production in the pep-CMC-PCL group was about
7 1.35 times than that of pep-CMC-glass sample at Day 21. With regard to hESCs, differing
8 from that of hiPSCs, ALP expression initially sharply reduced to a low level after 4 days of
9 osteogenic stimulation, whereafter it steadily elevated to 102.8 ± 5.6 U/gprot. The amount of
10 ALP production on the modified fibers was 1.27-fold that of its counterpart (pep-CMC-glass)
11 at Day 21, although there were no difference between two groups before 7 days of culture. In
12 spite of a little different result, the similarity between two hPSCs (i.e., hESCs and hiPSCs) in
13 promoted ALP activity was observed on the VN peptide-decorated surfaces, implying that the
14 nanofiber might have a positive impact on the osteogenesis of hPSCs. As mentioned above,
15 various studies have showed that nanofibrous topology serve as temporary ECM significantly
16 influences the differentiation of various cell types as well as EBs from hPSCs.^{15, 16, 49} These
17 results were further qualitatively confirmed *via* EHC staining of ALP at Day 14 and 21 (Fig.
18 S3), exhibiting a good time-dependent ALP expression. By comparison, the ALP-positive
19 areas were obviously larger and darker on pep-CMC-PCL nanofibers than on pep-CMC-glass,
20 suggesting the long-term stimulating effect of the presence of nanofibrous matrixes on hPSCs'
21 osteo-differentiation.
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

48 **3.4.3. Osteogenic biomarker expression**

49
50 Cells are capable of sensing and responding to the biophysical stimuli from the surrounding
51 microenvironment, triggering a cascade of intracellular events regulating the gene expression
52 involved in cell fate like differentiation. An in-depth study at molecular level is helpful to
53
54
55
56
57
58
59
60

1
2
3 better understand the differences between 3D nanofiber-hPSCs interaction and 2D plate-hPSCs
4 interaction. Therefore, the study revealed the typical osteo-specific genes expressions of hPSCs
5 grown on pep-CMC-PCL and pep-CMC-glass encoding Runx2, ALP, Col1a1, and OCN
6 (osteocalcin) assessed by quantitative real-time PCR for 7, 14 and 21 days. It is well-known that
7 Runx2 is the early and master transcription factor initiating the osteogenic lineage transcriptional
8 program, which contributes to up-regulation of various downstream bone-related genes such as
9 OCN and Col1a1 *via* binding to the core site of their enhancers or promoters.¹⁷ OCN is
10 considered the most-characteristic indicator for mature osteoblasts and mineralization at a late
11 stage of osteogenesis, and it accumulates and reaches the maximum amount in the calcified bone
12 due to its high affinity for apatite crystals.⁵⁰ Col1a1 gene is an osteo-special marker encoding the
13 pro- α 1 chains of type 1 collagen, which is an extracellular matrix and structural protein
14 contained in the bone ECM.⁵⁰ Among these osteo-related biomarkers, ALP is a membrane-bound
15 enzyme and plays an essential role in the early mineralization of the bone matrix through
16 hydrolysis of organic phosphates.⁵¹ The peak of Runx2 expression located on Day 14, in line
17 with previous studies, because the early marker Runx2 functionalized at the prior period and
18 began to degrade after completing its role. As shown in Fig. 10, the fold change in expression of
19 Runx2 and ALP for hiPSCs on pep-CMC-PCL nanofibers was more than that on pep-CMC-glass
20 groups at Day 14 and 21, however for hESCs, the higher un-regulation in Runx2 and ALP
21 expression on pep-CMC-PCL surface were only detected at Day 14 and 21, respectively. In
22 particular, the Col1a1 and OCN expression of mRNA when both hiPSCs and hESCs cell lines
23 were cultivated on the pep-CMC-PCL nanofibers remarkably outmatched those on the pep-
24 CMC-glass substrate from Day 14 to Day 21. These results showed that osteoblastic
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 differentiation of hPSCs strongly happened and more actively on 3D nanofibrous
4
5 microenvironment than 2D culture with plate surface.
6
7

8 To further verify the results from gene analysis on the peptide-decorated fibrous substrates,
9
10 the production of some osteogenesis-related makers including Runx2, Col1a1, OPN, and OCN,
11
12 as well as cytoskeletons stained by FITC-phalloidine were also probed through
13
14 immunofluorescence staining. Osteopontin (OPN), one of the most abundant non collagenous
15
16 proteins of bone matrix, plays a key role in the process of bone mineralization.⁵² At Day 7,
17
18 hiPSCs and hESCs subjected to the nanofibers were positive for Runx2 and slightly expressed
19
20 Nanog, a typical marker for an undifferentiated state of hPSCs, implying that hPSCs began to
21
22 lose their stemness. As osteoinductive time proceeded to Day 14, all cells strongly expressed a
23
24 production of Runx-2 marker but negative for Nanog (Fig. S4). In Fig. 11, nanofiber scaffolds
25
26 were visualized to blue color at 488 nm excitation wavelength. We could see that
27
28 differentiated cells attached onto the nanofibers very well, and they displayed a strong
29
30 expression of bone-specific ECM proteins such as Col1a1 (green), OPN (red), and OCN (red),
31
32 implying that nanofibrous structure could have an additive effect in enhancing the osteogenic
33
34 conversion of hPSCs. Moreover, the cytoskeletons in cells were also stained by FITC-
35
36 phalloidin after osteogenic stimulus of hPSCs on the peptide-decorated PCL fibers at Day 21.
37
38 In addition to cellular morphological alteration, most differentiated cells seeded on fibrous
39
40 samples exhibited favorable spreading by re-organized focal adhesions and filamentous F-
41
42 actin, and by outstretching lamellipodia, that were typical behaviors of osteoblasts cultured
43
44 on nanofiber surfaces reported in previous work.⁵³⁻⁵⁵ Furthermore, these cells stained strongly
45
46 positive for OCN, which is a biomarker for mature osteoblasts. Our current data from
47
48 foregoing osteogenic differentiation experiments supported the hypothesis that the combined
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 employment of classical osteoinductive media and nanofibrous scaffold greatly improved the
4
5 osteogenic efficiency of hPSCs, subsequently resulting in the acceleration of the osteogenesis.
6
7

8 As is well known, ECM is a complex mixture constituted of collagen-based nanofibrous
9
10 skeleton, structural proteins (e.g. vitronectin, and fibronectin), and glycosaminoglycans
11
12 (polysaccharides).⁵⁶ In the hPSCs culture niche, the oligopeptides from VN protein, a most
13
14 common cell adhesion motif, undoubtedly elicits an imperative role in attachment of hPSCs. The
15
16 structure of CMC is akin to glycosaminoglycans, which is documented to enhance the expression
17
18 of ECM in human osteoblasts and chondrocytes and stimulate the osto-differentiation of
19
20 osteoprogenitor cells.⁵⁷ On the other hand, CMC polysaccharide possesses a low
21
22 elasticity modulus close to ECM, and it is proof that a soft surface is conducive to hPSCs
23
24 culture.⁵⁸ Actually, in the physiological microenvironment of bone tissues, in addition to
25
26 biochemical cue, the 3D fibrous structure in bone ECM also guides many cell behaviors like
27
28 adhesion, migration proliferation and differentiation through providing adaptive accommodation
29
30 and a complex set of mechanotransductive stimulation associated with Wnt/catenin pathway,
31
32 Integrin-mediated pathway, and MAPK-dependent PPAR signaling pathway.^{59, 60} Lim et al.
33
34 found that the nanofiber topography itself was sufficient to regulate stem cell differentiation
35
36 through promoting the activation of the Wnt signaling pathway.^{59, 60} PHBHHx electrospun
37
38 nanofibers were reported by Wu et al. to effectively enhance the osteogenic differentiation of
39
40 MSCs *via* mediating the MAPK-dependent PPAR signaling pathway.⁶⁰ Numerous published
41
42 literature has demonstrated that nanotopographic features of synthetic fibers mimic ECM exert
43
44 robust influence on the osteogenic differentiation of stem cells because of their niche-mimicking
45
46 features.^{61, 62} Another important evidence from Deng and his co-workers is that the in-depth
47
48 pathway analysis revealed that focal adhesion kinase, Wnt, TGF- β , and MAPK pathways were
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 collectively involved in the activation of osteogenic differentiation in human bone marrow
4
5 mesenchyme stem cell (hBMSCs) on poly-l-lactide (PLLA) nanofibers.⁶³ However, they also
6
7
8 found that the extent of osteogenic differentiation on the fibrous scaffold was much lower but
9
10 similar rhythm of dynamic cellular behavior compared with that driven induced by chemical
11
12 osteogenic supplements, demonstrating that mechanotransduction from nanofibrous scaffolds
13
14 might trigger nonspecific and multilevel activation of osteogenic differentiation in stem cells.
15
16

17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Several previous reports have shown that nanofibrous scaffold containing poly(ether sulfone) (PES), and poly(L-lactic acid) (PLLA)^{16, 64} provide help to promote the osteogenic conversion of hPSCs through EBs formation. EBs are commonly adopted for hPSCs' differentiation because they mimic the three dimensionality of development during gastrulation and formation of the three germ layers *in vivo*. Nevertheless, the limitation of employing EBs for differentiation studies arises from the fact that the yield of desired cells is much lower than the initial amounts of cells.⁶⁵ It has previously been reported that EBs formation prior to chemically-induced osteogenic differentiation is not necessary and may, in fact, hamper osteogenic potential of hPSCs.^{66, 67} Besides, EBs displayed outgrowth on all surfaces but had already formed cell-cell contacts thus reducing cell-substrate contact, so it is a less-than-ideal model for investigation of cell-substrate influence.⁶⁸ Without EBs formation step, biomaterialized PEGDA-co-A6ACA matrices¹ and osteomimetic PLGA scaffolds⁶⁹ were recently developed to direct osteogenic differentiation of hESC. However, these developments required the materials to be pre-coated with Matrigel and ECM protein to promote initial attachment of hPSCs. Although there are a few work on osteoblastic differentiation of mouse iPSCs on the fibrous scaffolds surface, but studies focusing on human

1
2
3 iPSCs is missing. We try to investigate and verify that hPSCs can achieve high yield
4
5 differentiation into osteoblastic cells on the prepared peptide-decorated nanofibrous niche.
6
7 Simultaneously, classic β -glycerophosphate (β -GP), ascorbic acid (AA) and dexamethasone as
8
9 effective chemical-induced factors was added into osteogenic medium to trigger the
10
11 mineralization of hPSCs. In the present work, hPSCs were directly potentiated to osteogenic
12
13 commitment on our peptides-decorated surface without EBs process and Matrigel/ECM coating
14
15 (i.e., under chemically defined conditions) coupled with biochemical and biophysical cues,
16
17 which could provide an efficient and safe microenvironment for bone tissue engineering.
18
19 Furthermore, the degree of orientation and size of nanofibers were pointed out to have a
20
21 powerful impact on cell differentiation, hence, future work should include the comprehensive
22
23 exploration of physical factors including orientation degree and size of nanofibers in the
24
25 influence on the osteogenic differentiation of hPSCs.
26
27
28
29
30
31
32
33

34 4. CONCLUSION

35
36 In this study, we demonstrated a facile and cost-effective approach to produce a novel peptide-
37
38 decorated nanofibrous niche through combining electrostatic spinning of PCL with VN peptide
39
40 conjugation to modulate hPSC differentiation towards osteoblastic phenotype. The modified
41
42 nanofiber surfaces could support the proliferation and retain the pluripotency of hiPSCs and
43
44 hESCs in a fully-defined basal media (mTeSRTM1). More interestingly, the cellular morphology
45
46 observation, ALP activity assessment, and RT-PCR analysis combined with
47
48 immunofluorescence results demonstrated that hPSCs incubated on the peptide-decorated
49
50 micromilieu underwent enhanced osteogenic conversion *in vitro* without induction of
51
52 differentiation by EB formation. The osteogenic culture system without Matrigel coating has
53
54
55
56
57
58
59
60

1
2
3 merits of eradicating risks of viral and microbial contamination picked up from animal-derived
4
5 proteins. Therefore, this chemically-defined and safe 3D fibrous niche, that supports the whole
6
7 process from hPSCs culture to osteogenic commitment, has promising potential for bone
8
9 regenerative medicine and tissue engineering.
10
11

12 13 14 15 **ASSOCIATED CONTENT**

16 17 **Supporting Information**

18
19 Figures S1-S4 and Tables S1-S2. This material is available free of charge *via* the Internet at
20
21 <http://pubs.acs.org>
22
23
24

25 26 **AUTHOR INFORMATION**

27 28 **Corresponding Author**

29
30 *Dr. Yi Deng

31
32 School of Chemical Engineering, Sichuan University,
33
34 No.24 South Section 1, Yihuan Road, Chengdu 610065, China,
35
36 Email: 18210357357@163.com.
37

38
39 *Prof. Shicheng Wei

40
41 School and Hospital of Stomatology, Peking University,
42
43 No. 22 South Street, Zhongguancun, Haidian District, Beijing, 100081, China,
44
45 Email: weishicheng991@163.com.
46
47

48 49 **Author Contributions**

50
51 The manuscript was written through contributions of all authors. All authors have given approval
52
53 to the final version of the manuscript.
54
55
56
57
58
59
60

Notes

The authors declare no competing financial interest.

ACKNOWLEDGMENT

This work was funded by the National Natural Science Foundation of China (No. 81371697, 81571824), Peking University's 985 Grant, and the financial support from scientific research foundation of Sichuan University.

REFERENCES

- (1) Kang, H.; Wen, C.; Hwang, Y.; Shih, Y. R.; Kar, M.; Seo, S. W.; Varghese, S. *J. Mater. Chem. B* **2014**, *2*, 5676-5688.
- (2) Nelson, T. J.; Martinezfernandez, A.; Terzic, A. *Nat. Rev. Cardiol.* **2010**, *7*, 700-710.
- (3) Takahashi, K.; Yamanaka, S. *Cell* **2006**, *126*, 663-676.
- (4) Kim, J. B.; Zaehres, H.; Wu, G.; Gentile, L.; Ko, K.; Sebastiano, V.; Araúzobravo, M. J.; Ruau, D.; Han, D. W.; Zenke, M. *Nature* **2008**, *454*, 646-650.
- (5) Hughes, C. S.; Postovit, L. M.; Lajoie, G. A. *Proteomics* **2010**, *10*, 1886-1890.
- (6) Deng, Y.; Zhang, X.; Zhao, X.; Li, Q.; Ye, Z.; Li, Z.; Liu, Y.; Zhou, Y.; Ma, H.; Pan, G. *Acta Biomater.* **2013**, *9*, 8840-8850.
- (7) Saha, K.; Mei, Y.; Reisterer, C. M.; Pyzocha, N. K.; Yang, J.; Muffat, J.; Davies, M. C.; Alexander, M. R.; Langer, R.; Anderson, D. G. *P. Natl. Acad. Sci. USA* **2011**, *108*, 18714-18719.
- (8) Rowland, T. J.; Miller LMBlaschke, A. J.; Doss, E. L.; Bonham, A. J.; Hikita, S. T.; Johnson, L. V.; Clegg, D. O. *Stem Cells Dev.* **2010**, *19*, 1231-1240.

- 1
2
3 (9) Rodin, S.; Domogatskaya, A.; Strm, S.; Hansson, E. M.; Chien, K. R.; Inzunza, J.; Hovatta,
4 O.; Tryggvason, K. *Nat. Biotechnol.* **2010**, *28*, 611-615.
5
6
7 (10) Liu, L.; Yoshioka, M.; Nakajima, M.; Ogasawara, A.; Liu, J.; Hasegawa, K.; Li, S.; Zou, J.;
8 Nakatsuji, N.; Kamei, K. I. *Biomaterials* **2014**, *35*, 6259-6267.
9
10
11 (11) Brafman, D. A.; Chang, C. W.; Fernandez, A.; Willert, K.; Varghese, S.; Shu, C.
12 *Biomaterials* **2010**, *31*, 9135-9144.
13
14
15 (12) Kang, H.; Shih, Y. R. V.; Hwang, Y.; Wen, C.; Rao, V.; Seo, T.; Varghese, S. *Acta*
16 *Biomater.* **2014**, *10*, 4961-4970.
17
18
19 (13) Xu, C.; Inai, R.; Kotaki, M.; Ramakrishna, S. *Tissue Eng.* **2004**, *10*, 1160-1168.
20
21
22 (14) Wang, S.; Zhong, S.; Lim, C. T.; Nie, H. *J. Mater. Chem. B* **2015**, *3*, 3358-3366.
23
24
25 (15) Ko, E. K.; Jeong, S. I.; Rim, N. G.; Lee, Y. M.; Shin, H.; Lee, B. K. *Tissue Eng. A* **2008**, *14*,
26 2105-2119.
27
28
29 (16) Ardeshtyrlajimi, A.; Hosseinkhani, S.; Parivar, K.; Yaghmaie, P.; Soleimani, M. *Mol. Biol.*
30 *Rep.* **2013**, *40*, 4287-4294.
31
32
33 (17) Ravichandran, R.; Venugopal, J. R.; Sundarrajan, S.; Mukherjee, S.; Ramakrishna, S.
34 *Biomaterials* **2012**, *33*, 846-855.
35
36
37 (18) Ho, M. H.; Liao, M. H.; Lin, Y. L.; Lai, C. H.; Lin, P.; Chen, R. M. *Int. J. Nanomed.* **2014**,
38 9, 4293-4304.
39
40
41 (19) Higuchi, A.; Kumar, S. S.; Ling, Q-D.; Alarfaj, A. A.; Munusamy, M. A.; Murugan, K.; Hsu,
42 S-T.; Benelli, G.; Umezawa, A. *Prog. Polym. Sci.* **2016**,
43 <http://dx.doi.org/10.1016/j.progpolymsci.2016.09.002>.
44
45
46 (20) Higuchi, A.; Ling, Q. D.; Kumar, S. S.; Munusamy, M.; Alarfaj, A. A.; Umezawa, A.; Wu,
47 G. J. *Prog. Polym. Sci.* **2014**, *39*, 1348-1374.
48
49
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3 (21) Dong, X.; Li, H.; Zhou, Y.; Ou, L.; Cao, J.; Chang, J. *J. Mater. Chem. B* **2016**, *4*, 2369-
4
5 2376.
6
7
8 (22) Higuchi, A.; Ling, Q. D.; Kumar, S. S.; Chang, Y.; Alarfaj, A. A.; Munusamy, M. A.;
9
10 Murugan, K.; Hsu, S. T.; Umezawa, A. *J. Mater. Chem. B* **2015**, *3*, 8032-8058.
11
12 (23) Cipitria, A. *J. Mater. Chem.* **2011**, *21*, 9419-9453.
13
14 (24) Villa-Diaz, L. G.; Nandivada, H.; Ding, J.; Nogueira-De-Souza, N. C.; Krebsbach, P. H.;
15
16 O'Shea, K. S.; Lahann, J.; Smith, G. D. *Nat. Biotechnol.* **2010**, *28*, 581-583.
17
18 (25) Bhattacharya, D.; Das, M.; Mishra, D.; Banerjee, I.; Sahu, S. K.; Maiti, T. K.; Pramanik, P.
19
20 *Nanoscale* **2011**, *3*, 1653-1662.
21
22 (26) Chen, R. N.; Wang, G. M.; Chen, C. H.; Ho, H. O.; Sheu, M. T. *Biomacromolecules* **2006**,
23
24 *7*, 1058-1064.
25
26 (27) Shi, Z.; Neoh, K. G.; Kang, E. T.; Poh, C. K.; Wang, W. *Biomacromolecules* **2009**, *10*,
27
28 1603-1611.
29
30 (28) Budiraharjo, R.; Neoh, K. G.; Kang, E. T. *J. Colloid Interf. Sci.* **2012**, *366*, 224-232.
31
32 (29) Danesin, R.; Brun, P.; Roso, M.; Delaunay, F.; Samouillan, V.; Brunelli, K.; Iucci, G.;
33
34 Ghezzi, F.; Modesti, M.; Castagliuolo, I. *Bone* **2012**, *51*, 851-859.
35
36 (30) Chen, S. C.; Wu, Y. C.; Mi, F. L.; Lin, Y. H.; Yu, L. C.; Sung, H. W. *J. Control. Release*
37
38 **2004**, *96*, 285-300.
39
40 (31) Nandakumar, A.; Tahmasebi, B. Z.; Santos, D.; Mentink, A.; Auffermann, N.; Van, d. W.
41
42 K.; Bennink, M.; Moroni, L.; Van, B. C.; Habibovic, P. *Biofabrication* **2013**, *5*, 015006.
43
44 (32) Wang, H.; Kwok, D. T. K.; Xu, M.; Shi, H.; Wu, Z.; Zhang, W.; Chu, P. K. *Adv. Mater.*
45
46 **2012**, *24*, 3315-3324.
47
48
49
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3 (33) Wilkinson, A.; Hewitt, R. N.; Mcnamara, L. E.; Mccloy, D.; Meek, R. M. D.; Dalby, M. J.
4
5 *Acta Biomater.* **2011**, *7*, 2919-2925.
6
7
8 (34) Azeem, A.; English, A.; Kumar, P.; Satyam, A.; Biggs, M.; Jones, E.; Tripathi, B.; Basu, N.;
9
10 Henkel, J.; Vaquette, C. *Nanomedicine* **2015**, *10*, (5), 693-711.
11
12
13 (35) Xu, A.; Liu, X.; Xiang, G.; Feng, D.; Yi, D.; Wei, S. *Mat. Sci. Eng. C* **2015**, *48*, 592-598.
14
15 (36) Park, H. J.; Yang, K.; Kim, M. J.; Jang, J.; Lee, M.; Kim, D. W.; Lee, H.; Cho, S. W.
16
17 *Biomaterials* **2015**, *50*, 127-139.
18
19
20 (37) Gao, X.; Zhang, X.; Song, J.; Xu, X.; Xu, A.; Wang, M.; Xie, B.; Huang, E.; Deng, F.; Wei,
21
22 S. *Inter. J. Nanomed.* **2015**, *10*, 7109-7128.
23
24
25 (38) Jing, X.; Mi, H. Y.; Peng, J.; Peng, X. F.; Turng, L. S. *Carbohydr. Polym.* **2015**, *117*, 941-
26
27 949.
28
29 (39) Hu, B. Y.; Weick, J. P.; Yu, J.; Ma, L. X.; Zhang, X. Q.; Thomson, J. A.; Zhang, S. C. *P.*
30
31 *Natl. Acad. Sci. USA* **2010**, *107*, 4335-4340.
32
33
34 (40) Song, Z.; Cai, J.; Liu, Y.; Zhao, D.; Yong, J.; Duo, S.; Song, X.; Guo, Y.; Zhao, Y.; Qin, H.;
35
36 Yin, X.; Wu, C.; Che, J.; Lu, S.; Ding, M.; Deng, H. *Cell Research* **2009**, *19*, 1233-1242.
37
38
39 (41) Chen, Y-F.; Tseng, C-Y.; Wang, H-W.; Kuo, H-C.; Yang V. W.; Lee, O. K. *Hepatology*,
40
41 **2012**, *55*, 1193-1203.
42
43
44 (42) Lian, X.; Hsiao, C.; Wilson, G.; Zhu, K.; Hazeltine, L. B.; Azarin, S. M.; Raval, K. K.;
45
46 Zhang, J.; Kamp, T. J.; Palecek, S. P. *P. Natl. Acad. Sci. USA*, **2012**, *109*, 4933-4942.
47
48
49 (43) Burridge, P.; Keller, G.; Gold, J.; Wu, J. *Cell Stem Cell* **2012**, *10*, 16-28.
50
51
52 (44) Charles, A. E. IV; Phillips, B.; Mcguire, M.; Barringer, J.; Valli, H.; Hermann, B.; Simerly,
53
54 C.; Rajkovic, A.; Miki, T.; Orwig, K. *Cell Reports* **2011**, *2*, 440-446.
55
56 (45) Li, Y. J.; Chung, E. H.; Rodriguez, R. T. *J. Biomed. Mater. Res. A* **2006**, *79A*, 1-5.
57
58
59
60

- 1
2
3
4 (46) Lu, H. F.; Narayanan, K.; Lim, S.-X.; Gao, S.; Leong, M. F.; Wan, A. C. A. *Biomaterials*
5 **2012**, *33*, 2419-2430.
6
7
8 (47) Reubinoff, B. E.; Pera, M. F.; Fong, C. Y.; Trounson, A.; Bongso, A. *Nat. Biotechnol.* **2000**,
9 *18*, 399-404.
10
11
12 (48) Schopperle, W. M.; Dewolf, W. C. *Stem Cells* **2007**, *25*, 723-730.
13
14
15 (49) Christopherson, G. T.; Song, H.; Mao, H. Q. *Biomaterials* **2009**, *30*, 556-564.
16
17
18 (50) Kaur, G.; Valarmathi, M. T.; Potts, J. D.; Wang, Q. *Biomaterials* **2008**, *29*, 4074-81.
19
20 (51) Liu, W.; Lipner, J.; Xie, J.; Manning, C. N.; Thomopoulos, S.; Xia, Y. *ACS Appl. Mater.*
21 *Inter.* **2011**, *6*, 2842-2849.
22
23
24 (52) Yin, L.; Cheng, W.; Qin, Z.; Yu, H.; Yu, Z.; Zhong, M.; Sun, K.; Zhang, W. *Stem Cells Int.*
25 **2015**, *2015*, 1-9.
26
27
28 (53) Sachar, A.; Strom, T. A.; Serrano, M. J.; Benson, M. D.; Opperman, L. A.; Svoboda, K. K.
29 H.; Liu, X. *J. Biomed. Mater. Res. A* **2012**, *100*, 3029-3041.
30
31
32 (54) Horii, A.; Wang, X.; Gelain, F.; Zhang, S. *Plos One* **2007**, *2*, e190.
33
34
35 (55) Lee, Y. J.; Lee, J. H.; Cho, H. J.; Kim, H. K.; Yoon, T. R.; Shin, H. *Biomaterials* **2013**, *34*,
36 5059-69.
37
38
39 (56) Frantz, C.; Stewart, K. M.; Weaver, V. M. *J. Cell Sci.* **2010**, *123*, 4195-200.
40
41
42 (57) Lahiji, A.; Sohrabi, A.; Hungerford, D. S.; Frondoza, C. G. *J. Biomed. Mater. Res.* **2000**, *51*,
43 586-595.
44
45
46 (58) Chowdhury, F.; Li, Y.; Poh, Y. C.; Yokohama-Tamaki, T.; Wang, N.; Tanaka, T. S. *Plos*
47 *One* **2010**, *5*, e15655.
48
49
50 (59) Lim, S. H.; Liu, X. Y.; Song, H.; Yarema, K. J.; Mao, H. Q. *Biomaterials* **2010**, *31*, 9031-
51 9039.
52
53
54
55
56
57
58
59
60

- 1
2
3 (60) Wang, Y.; Gao, R.; Wang, P. P.; Jian, J.; Jiang, X. L.; Yan, C.; Lin, X.; Wu, L.; Chen, G.
4
5 Q.; Wu, Q. *Biomaterials* **2012**, *33*, 485-493.
6
7
8 (61) Zhu, H.; Cao, B.; Zhen, Z.; Laxmi, A. A.; Li, D.; Liu, S.; Mao, C. *Biomaterials* **2011**, *32*,
9
10 4744-4752.
11
12 (62) Hu, J.; Liu, X.; Ma, P. X. *Biomaterials* **2008**, *29*, 3815-3821.
13
14 (63) Liu, W.; Wei, Y.; Zhang, X.; Xu, M.; Yang, X.; Deng, X. *ACS Nano* **2013**, *7*, 6928-6938.
15
16 (64) Smith, L. A.; Liu, X.; Jiang, H.; Ma, P. X. *Biomaterials* **2010**, *31*, 5526-5535.
17
18 (65) Dang, S. M.; Kyba, M.; Perlingeiro, R.; Daley, G. Q.; Zandstra, P. W. *Biotechnol. Bioeng.*
19
20 **2002**, *78*, 442-453.
21
22 (66) Karp, J. M.; Ferreira, L. S.; Khademhosseini, A.; Kwon, A. H.; Yeh, J.; Langer, R. S. *Stem*
23
24 *Cells* **2006**, *24*, 835-843.
25
26 (67) Kärner, E.; Unger, C.; Sloan, A. J.; Ahrlundrichter, L.; Sugars, R. V.; Wendel, M. *Stem*
27
28 *Cells Dev.* **2007**, *16*, 39-52.
29
30 (68) Kingham, E.; White, K.; Gadegaard, N.; Dalby, M. J.; Oreffo, R. O. C. *Small* **2013**, *9*, 2140-
31
32 51.
33
34 (69) Rutledge, K.; Cheng, Q.; Pryzhkova, M.; Harris, G. M.; Jabbarzadeh, E. *Tissue Eng. C*,
35
36 **2014**, *20*, 865-874.
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Captions of Figures and Tables

Fig. 1. Schematic illustration of the fabrication of peptide-decorated nanofibrous microenvironment, and *in vitro* culture and directed osteogenic induction of hPSCs on the fibrous niche.

Fig. 2. ATR-FT-IR spectra (a), water contact angles and corresponding surface energy (b) of the pristine and functionalized PCL nanofibrous scaffolds (CMC-PCL, and pep-CMC-PCL).

Fig. 3. XPS survey scan spectra: XPS wide spectra (a); high-resolution spectra of carbon peaks (C 1s) for the pristine PCL (b), CMC-PCL (c) and pep-CMC-PCL (c).

Fig. 4. SEM and corresponding AFM images of the (a) pristine PCL, (b) CMC-coated PCL and (c) peptide-decorated PCL nanofibers samples.

Fig. 5. The proliferation of hiPSCs (a) and hESCs (b) on the surface of peptide-decorated PCL nanofibrous scaffold with different culture time.

Fig. 6. SEM observation of adhering hPSCs on the peptide-decorated nanofibers from 1 day to 5 days.

Fig. 7. Fluorescence micrographs of colonies of hPSCs cultured on the peptide-decorated substrate at 1 day and 3 days in mTeSRTM1 media visualized by laser confocal microscopy, showing expression of hPSC markers: Oct-4, Tra-1-60, SSEA-3 and SSEA-4.

Fig. 8. hiPSCs (a) and hESCs (b) morphology changes during osteo-differentiation on peptide-decorated PCL nanofibers under osteogenic inducing medium at various culture times. Red arrows point to the filopodia of the differentiated cells adhered to the substrate. The scale bar indicates 50 μm .

Fig. 9. ALP activity of hiPSCs (a) and hESCs (b) cultured on pep-CMC-PCL nanofibers and pep-CMC-glass surfaces. *represents $p < 0.05$ between groups.

1
2
3 **Fig. 10.** Real-time PCR detection of osteogenesis-related gene expression (Runx2, ALP, Col1a1,
4 and OCN) of hiPSCs and hESCs incubated on the two peptide-decorated samples at Day 7, 14
5 and 21. *represents $p < 0.05$ compared with pep-CMC-glass, and **represents $p < 0.01$ compared
6 with pep-CMC-glass.
7
8
9
10
11

12 **Fig. 11.** Immunofluorescent images of Col1a1 (green), OPN (red), OCN (red), and cytoskeleton
13 (green) on the peptide-decorated nanofiber substrates at Day 21. Col1a1 and cytoskeleton were
14 labeled by green fluorescence, whereas OPN and OCN were marked by green fluorescence.
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Nanofiber were visualized to blue color at 488 nm excitation wavelength.




Fig. 1. Schematic illustration of the fabrication of peptide-decorated nanofibrous microenvironment, and *in vitro* culture and directed osteogenic induction of hPSCs on the fibrous niche.




Fig. 2. ATR-FT-IR spectra (a), water contact angles and corresponding surface energy (b) of the pristine and functionalized PCL nanofibrous scaffolds (CMC-PCL, and pep-CMC-PCL).




Fig. 3. XPS survey scan spectra: XPS wide spectra (a); high-resolution spectra of carbon peaks (C 1s) for the pristine PCL (b), CMC-PCL (c) and pep-CMC-PCL (c).




Fig. 4. SEM and corresponding AFM images of the (a) pristine PCL, (b) CMC-coated PCL and (c) peptide-decorated PCL nanofibers samples.




Fig. 5. The proliferation of hiPSCs (a) and hESCs (b) on the surface of peptide-decorated PCL nanofibrous scaffold with different culture time.




Fig. 6. SEM observation of adhering hPSCs on the peptide-decorated nanofibers from 1 day to 5 days.




Fig. 7. Fluorescence micrographs of colonies of hPSCs cultured on the peptide-decorated substrate at 1 day and 3 days in mTeSR™1 media visualized by laser confocal microscopy, showing expression of hPSC markers: Oct-4, Tra-1-60, SSEA-3 and SSEA-4.




Fig. 8. hiPSCs (a) and hESCs (b) morphology changes during osteo-differentiation on peptide-decorated PCL nanofibers under osteogenic inducing medium at various culture times. Red arrows point to the filopodia of the differentiated cells adhered to the substrate. The scale bar indicates 50 μm .




Fig. 9. ALP activity of hiPSCs (a) and hESCs (b) cultured on pep-CMC-PCL nanofibers and pep-CMC-glass surfaces. *represents $p < 0.05$ between groups.




Fig. 10. Real-time PCR detection of osteogenesis-related gene expression (Runx2, ALP, Colla1, and OCN) of hiPSCs and hESCs incubated on the two peptide-decorated samples at Day 7, 14 and 21. *represents $p < 0.05$ compared with pep-CMC-glass, and **represents $p < 0.01$ compared with pep-CMC-glass.





Fig. 11. Immunofluorescent images of Colla1 (green), OPN (red), OCN (red), and cytoskeleton (green) on the peptide-decorated nanofiber substrates at Day 21. Colla1 and cytoskeleton were labeled by green fluorescence, whereas OPN and OCN were marked by green fluorescence.

Nanofiber were visualized to blue color at 488 nm excitation wavelength.

Table of Contents Graphic

For Table of Contents Use Only



Peptide-decorated nanofibrous niche augments in vitro directed osteogenic conversion of human pluripotent stem cells

Yi Deng, Yuanyi Yang, Shicheng Wei